Scinus Cell Expansion and ATMP-Center at Skåne University Hospital Partner for Advances in Cell Therapy
During BIO-Europe in Stockholm, Scinus Cell Expansion marked a significant step forward in establishing a collaborative relationship with Region Skåne by signing a Letter of Intent with the ATMP-Center at Skåne University Hospital. Together, our aim is to drive...
Ask the Expert: PhD Student Javier Olmos Becerra on HEK293T culture using the SCINUS bioreactor NG
In our previous blogpost, we shed a light on all the different possibilities that HEK293T cells have to offer. Now, in this second edition of our 'Ask the Expert' series, we will interview our PhD student Javier Olmos Becerra. He’s been working on optimizing HEK293T...
Using HEK293T Cells to Produce Viral Vectors for Gene Therapy
HEK293T cells, derived from human embryonic kidney cells, are widely used in gene therapy research due to their transfection efficiency and capability to produce different types of viral vectors. These cells are especially suitable for generating lentiviral (LV)...
Bioprocessing Summit Boston
Scinus Cell Expansion is attending the Bioprocessing Summit in Boston! From 19th till 22nd of August, Scinus Cell Expansion will be attending the 16th annual Bioprocessing Summit in Boston! We’re excited to discuss today’s challenges and advances in bioprocess R&D...
Organoid Culture: The potential to revolutionize disease modeling
Organoids have emerged as a revolutionary tool in drug discovery and clinical practice. These miniature 3D structures, cultivated from stem cells or differentiated cells, mimic the architecture and function of organs, offering a significant advancement over...
New Location!
Scinus Cell Expansion is moving to Zeist As of June 1st, Scinus Cell Expansion will be located at the Utrecht Science Park location in Zeist! This place provides a vibrant, dynamic and exciting place to work, where industry and academia come together. Feel free to...
Ask the Expert: Process Development Engineer Juda-El Sam on iPSC culture using the SCINUS bioreactor NG
To standardize iPSC differentiation and production to a level necessary for producing therapy grade cells, Process Development Engineer Juda-El Sam from Scinus Cell Expansion is working on developing protocols for iPSC expansion using the SCINUS bioreactor NG. “At the...
iPSCs for personalized cell therapy: prospects and remaining challenges
The unique nature of induced pluripotent stem cells (iPSCs) lies in their capability for unlimited self–renewal and programmed differentiation into virtually any adult cell types [1]. iPSC based technology holds the potential to treat a multitude of diseases and...
Scinus recognized as one of the Top Cell Therapy Companies In Europe by Life Sciences Review
SCINUS simplifies operational procedures and significantly diminishes the overall cost of ownership.
The Potential of AI in Cell Therapy and bioreactor systems.
Bioprocess control and continuous process improvement are crucial for the evolving field of cell therapy development and bioreactors. Combination of the current control and optimization technologies with the latest computer-based strategies will accelerate the path...